1.
Nat Cancer
; 2(8): 794-802, 2021 08.
Article
in English
| MEDLINE
| ID: mdl-35118423
ABSTRACT
Only a minority of patients derive long-term clinical benefit from anti-PD1/PD-L1 monoclonal antibodies. The presence of tertiary lymphoid structures (TLS) has been associated with improved survival in several tumor types. Here, using a large-scale retrospective analysis of three independent cohorts of cancer patients treated with anti-PD1/PD-L1 antibodies, we showed that the presence of mature TLS was associated with improved objective response rate, progression-free survival, and overall survival independently of PD-L1 expression status and CD8+ T-cell density. These results pave the way for using TLS detection to select patients who are more likely to benefit from immune checkpoint blockade.
Subject(s)
Lung Neoplasms , Tertiary Lymphoid Structures , Antibodies, Monoclonal/therapeutic use , B7-H1 Antigen/therapeutic use , Humans , Immune Checkpoint Inhibitors/pharmacology , Lung Neoplasms/drug therapy , Retrospective Studies
2.